Table 1.
Group | Number of patients [n] | Tumor stage [TNM] | Median age (range) [years] | Number of patients [f/m] |
---|---|---|---|---|
1 | 7 | T3N + M0 (18–36 months) | 73 (66–87) | 2/5 |
2 | 6 | T3N + M0 (72–110 months) | 77 5(53–84) | 1/5 |
3 | 17 | T3N + M1 (synchronous) | 64 (26–86) | 8/9 |
4 | 17 | T3N + M1 (metachronous) | 72 (39–83) | 7/10 |
5 | 3 | TxN2M0 | 71 (56–86) | 3/0 |
6 | 4 | T2N0M1 | 63 (56–68 | 1/3 |
7 | 9 | T4N0M0 | 78 (51–91) | 2/7 |
Group 1 describes T3 CRC tumors with lymph node metastases (N+) but no distant metastases (M0) with a postoperative survival between 18 and 36 months. Group 2 consisted of patients with T3N + M0 CRC tumors with a postoperative survival between 72 and 110 months. Group 3 and 4 display patients with advanced CRC (T3N+) having distant metastases (M1) either of synchronous (group 3) or metachronous (group 4) type. Group 5 included CRC with extended lymph node metastases (N2), whereas group 6 included CRC tumors with early distant metastases (T2N0M1). Group 7 displays locally advanced CRC tumors (T4) with no lymph node or distant metastases (N0 and M0)